LAST WEEK TODAY! A summary of what was published on ProstateWarriors.com during the past week Hi fellow warriors! This week the focus is on preclinical research. The fact that the AACR Annual Meeting 2026 is starting in less than a month means there are a lot of interesting new developments in the preclinical field. I’ll try to […]
JMKX007129 is a new small‑molecule drug that targets the N‑terminal domain (NTD) of the androgen receptor (AR) in prostate cancer. It is designed to overcome resistance seen with current AR‑ligand binding domain (LBD) inhibitors, which often stop working in castration‑resistant prostate cancer (CRPC) when AR develops mutations or produces splice variants like AR‑V7. JMKX007129 builds […]
AUTOTACs (Autophagy‑Targeting Chimeras), are molecules designed to force cancer cells to “clean up” and destroy the androgen receptor (AR), a key driver of prostate cancer growth and progression. The latest research on two second‑generation AR‑targeting AUTOTACs, ATB‑238 and ATB‑239, shows that these compounds can effectively degrade not only the normal AR but also its troublesome […]
RAX104 is a small molecule ligand designed specifically to target PSMA, the protein that is highly expressed on the surface of prostate cancer cells. When labeled with ²²⁵Ac, it forms a radioligand that combines the physical advantages of actinium‑225 (high linear energy transfer and a 10‑day half‑life) with a ligand engineered for better tumor retention. […]
HLX3902 is a STEAP1×CD3×CD28 trispecific T‑cell engager developed as a potential first‑in‑class immunotherapy for prostate cancer. Prostate tumors are largely “cold” from an immunological standpoint. The microenvironment is immunosuppressive, T cells are scarce inside the tumor mass, and those that do infiltrate often burn out quickly after activation. Classical CD3‑only bispecific TCEs can force T […]
Chemical‑induced proximity (CIP) strategies have expanded the therapeutic toolbox by modulating protein–protein interactions, but classical approaches such as PROTACs and molecular glues often force unnatural pairings or stabilize existing interfaces, leading to variable or unpredictable effects. Domain‑ALTeration Chimeras (DALTACs) take a different path: instead of degrading targets or reinforcing native contacts, they selectively miswire endogenous […]
A new experimental drug called TBI‑001 targets a protein called TRIB2 in advanced prostate cancer that has become resistant to hormone therapy and starts acquiring neuroendocrine features. This is particularly relevant for treatment‑emergent neuroendocrine prostate cancer (t‑NEPC), a lethal subtype that arises after long‑term androgen‑receptor–targeted therapy, loses dependence on AR signaling, and adopts a neuroendocrine […]
Most prostate cancer treatments today target the part of the AR protein that binds hormones, known as the ligand‑binding domain or LBD. At first these drugs like enzalutamide and abiraterone can shrink tumors or slow progression, but over time the cancer adapts and becomes resistant. This adaptation is a major reason why men with mCRPC […]
A novel approach to targeting androgen receptor signaling in prostate cancer is emerging with FX‑111, an experimental degrader that selectively removes the hormone‑bound, transcriptionally active form of the receptor known as ARon. In metastatic castration‑resistant prostate cancer (mCRPC), the androgen receptor remains a central driver in the vast majority of cases, yet resistance to current […]
A large real‑world study in nonmetastatic castration‑resistant prostate cancer (nmCRPC) called DEAR‑EXT, published on Nature, has added new detail to how the three androgen receptor inhibitors (darolutamide, enzalutamide, and apalutamide) behave outside of randomized trials, using data from over 1,300 men treated in US urology practices between 2019 and 2023. The analysis builds on an […]
This site uses cookies. By continuing to browse the site, you are agreeing to our use of cookies.
Accept settingsHide notification onlySettingsWe may request cookies to be set on your device. We use cookies to let us know when you visit our websites, how you interact with us, to enrich your user experience, and to customize your relationship with our website.
Click on the different category headings to find out more. You can also change some of your preferences. Note that blocking some types of cookies may impact your experience on our websites and the services we are able to offer.
These cookies are strictly necessary to provide you with services available through our website and to use some of its features.
Because these cookies are strictly necessary to deliver the website, refusing them will have impact how our site functions. You always can block or delete cookies by changing your browser settings and force blocking all cookies on this website. But this will always prompt you to accept/refuse cookies when revisiting our site.
We fully respect if you want to refuse cookies but to avoid asking you again and again kindly allow us to store a cookie for that. You are free to opt out any time or opt in for other cookies to get a better experience. If you refuse cookies we will remove all set cookies in our domain.
We provide you with a list of stored cookies on your computer in our domain so you can check what we stored. Due to security reasons we are not able to show or modify cookies from other domains. You can check these in your browser security settings.
These cookies collect information that is used either in aggregate form to help us understand how our website is being used or how effective our marketing campaigns are, or to help us customize our website and application for you in order to enhance your experience.
If you do not want that we track your visit to our site you can disable tracking in your browser here:
We also use different external services like Google Webfonts, Google Maps, and external Video providers. Since these providers may collect personal data like your IP address we allow you to block them here. Please be aware that this might heavily reduce the functionality and appearance of our site. Changes will take effect once you reload the page.
Google Webfont Settings:
Google Map Settings:
Google reCaptcha Settings:
Vimeo and Youtube video embeds:
The following cookies are also needed - You can choose if you want to allow them:
You can read about our cookies and privacy settings in detail on our Privacy Policy Page.
Privacy Policy